Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience

ConclusionsIn the first observational study of selumetinib for NF-1 associated PN we showed that the drug was associated with clinical and radiological improvement. Our study also confirms the safety described in the clinical trials.

Source: Journal of Neuro-Oncology - February 26, 2020 Category: Cancer & Oncology Source Type: research